Skip to main content
Skip to main navigation
Search for :
Product Development Strategy
Early Clinical Development
Phase I/IIa Clinical Trials
Phase II/III Clinical Trials
Interventional Phase IIIb/Phase IV Clinical Trials
Observational Research & Registries
Product Launch & Management
Market Access Solutions
Strategic Sales Outsourcing
Biopharmaceutical Sales & Marketing
Healthcare Payers & Providers
Medical Device & Diagnostics
Public Health & Government
Specialty Clinical Associations and Patient Organizations
Central Nervous System
Diabetes & Endocrinology
Early Phase Oncology
Public Health Interest
Other Therapeutic Areas
Ethics & Compliance
by Product Lifecycle
Phone:+1 866 267 4479
Request a Proposal
Phone:400 881 0237
Phone:01 208 94 060
Phone:+44 203 564 4649
Biostatistics in clinical trials isn’t just a necessity. With the right approach, it can be a competitive advantage.
Founded by biostatisticians, Quintiles harnesses the power of clinical data analysis to fuel clinical trial success. Leveraging biostatistics in the planning stages of your drug development program, we can help you:
Effective Analysis and Reporting
Effective Analysis and Reporting is crucial to accurately packaging the evidence from your trial in your regulatory dossier.
Real-time Data and Patient Safety
In light of a recent FDA guidance, Andrew Garrett, Global Head of Biostatistics, Medical Writing and Regulatory Affairs for Quintiles, discusses how real-time collection of clinical research data can accelerate development timelines and better ensure patient safety.
Listen to podcast
Combining Analysis Results from Multiply Imputed Categorical Data
Multiple imputation (MI) is a methodology for dealing with missing data that has been steadily gaining wide usage in clinical trials. Read our paper which won Best in Biostatistics and Pharmacokinetics at the 2013 PharmaSUG Conference.
Beyond Tables and P-values: Enhancing the Role of the Clinical Trial Team Statistician
Sonia Davis discusses "Beyond Tables and P-values: Enhancing the Role of the Clinical Trial Team Statistician" at the FDA/Industry Statistics Workshop, on September 20, 2011.